Hackenberg R, Hofmann J, Hölzel F, Schulz K D
Zentrum für Frauenheilkunde, Universität Marburg, Federal Republic of Germany.
J Cancer Res Clin Oncol. 1988;114(6):593-601. doi: 10.1007/BF00398183.
The proliferation of three mammary carcinoma cell lines was explored for the effectiveness of dihydrotestosterone (DHT) and the antiandrogenic substances cyproterone acetate (CPA) or hydroxyflutamide. The cell growth, determined in multiple experimental cultures of the estrogen-sensitive lines MCF-7 and EFM-19, was stimulated by 10(-9) M to 10(-6) M DHT, whereas estrogen-resistant MFM-21 cells were unresponsive to the hormonal factors applied. Growth-promoting effects of 10(-8) M to 10(-6) M CPA were detected in cultures of those cell lines which were sensitive to estrogen and androgen. Competition experiments with DHT and the antiandrogens suggested involvement of the androgen receptor in the stimulation of cell growth by CPA. Participation of the estrogen receptor was excluded by lack of competition between CPA and the enhancement of proliferation by estradiol-17 beta. At the receptor level the antiandrogens were able to compete with androgen binding. The results of the study demonstrate androgenic properties of CPA in regard to the growth of human mammary carcinoma cells.
研究了三种乳腺癌细胞系的增殖情况，以探究二氢睾酮（DHT）以及抗雄激素物质醋酸环丙孕酮（CPA）或氟他胺的有效性。在雌激素敏感细胞系MCF-7和EFM-19的多次实验培养中测定细胞生长情况，结果显示10⁻⁹ M至10⁻⁶ M的DHT能刺激细胞生长，而雌激素抵抗性的MFM-21细胞对所应用的激素因子无反应。在对雌激素和雄激素敏感的细胞系培养物中检测到10⁻⁸ M至10⁻⁶ M的CPA具有促生长作用。DHT与抗雄激素的竞争实验表明，雄激素受体参与了CPA对细胞生长的刺激作用。由于CPA与17β-雌二醇之间缺乏竞争以及对增殖的增强作用，排除了雌激素受体的参与。在受体水平上，抗雄激素能够与雄激素结合竞争。该研究结果表明，就人乳腺癌细胞生长而言，CPA具有雄激素特性。
